Profil
Geoffrey Norman Vaughan served as a Non-Executive Director at Idt Australia Ltd.
from 1997 to 2012 and at Cytopia Ltd.
from 2010 to 2011.
He also held positions as National Manager at Therapeutic Goods Administration and Member-Industry Research & Development Board at Australia Department of Industry, Tourism & Resources.
Anciens postes connus de Geoffrey Norman Vaughan
| Sociétés | Poste | Fin |
|---|---|---|
| IDT AUSTRALIA LIMITED | Directeur/Membre du Conseil | 30/06/2012 |
Cytopia Ltd.
 Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | Directeur/Membre du Conseil | 26/07/2011 |
| Australia Department of Industry, Tourism & Resources | Corporate Officer/Principal | - |
| Therapeutic Goods Administration | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IDT AUSTRALIA LIMITED | Health Technology |
| Entreprise privées | 3 |
|---|---|
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | Health Technology |
| Therapeutic Goods Administration | |
| Australia Department of Industry, Tourism & Resources | Government |